TABLE 3.
Role and potential benefits of vitamin C on various organ systems, adapted from; all described benefits were derived from clinical studies unless stated explicitly.
| Patient group/Afflicted organ system | Special role of vitamin C in the organ system | Pathology/Condition studied | Pathophysiology related to potential usefulness of vitamin C |
Benefits from vitamin C administration | ||||||
| Described benefits of vitamin C in the organ system/Condition | Described or potential mechanisms through which vitamin C may be beneficial | |||||||||
| Mitigation of oxidative stress + restoration of other antioxidants | Improved endothelial function and microcirculation | Improved vasopressor response | Improved platelet function and decreased capillary plugging | Reduced extravasation and edema | Enhanced immune function and antibacterial properties | |||||
| Central nervous system | ● Elevated levels up to 80 times to protect neurons (92, 93) ● Essential for the differentiation and myelinization of neurons (94, 95) |
Stroke/Cerebral ischemia | ● I/R injury and subsequent oxidative stress ● Shift of vitamin C from the intra- to extracellular compartment and intraneuronal vitamin C deficiency (75) |
● Reduces infarct volume in experimental models (83–85) ● Decreases ischemic stroke-related lipid peroxidation (96) |
× | × | × | × | ||
| ICB Head trauma |
● Hemorrhage/tissue damage ● Increased ICP and subsequent reduction of cerebral perfusion |
● Inversely correlated with major diameter of lesion and severity of neurological impairment (97) | × | × | × | × | × | × | ||
| Cardiovascular system | ● Frequent vitamin C deficiency (98) ● Vasopressor synthesis |
Cardiac surgery Post-reanimation |
● I/R Injury and subsequent oxidative stress ● Hemodilution and extracorporeal circulation ● Compromised cardiac function and hemodynamics |
● Decreases myocardial injury (99) and higher cardiac index (99) ● Decreases rate of post-op arrhythmia (76–82), ICU (76, 79, 80) and hospital stay (76, 79–81, 100) and ventilation time (76, 77, 81) ● Decreases bleeding (101) |
× | × | × | × | × | × |
| CAD and MI | ● Chronic inflammatory disease leading to increased need of antioxidants | ● Promotes endothelial and NO dependent vasodilation ● Reduces AKI after coronary angiography (89) |
× | × | × | × | ||||
| Respiratory system | ● High levels in alveolar type II cells and macrophages (102) ● Collagen synthesis, endothelial restoration and alveolar proliferation (103) |
ARDS Pneumonia COPD Asthma Cystic fibrosis |
● Most common organ system to suffer from reactive oxygen species (103) ● Acute or chronic inflammation leading to increased need of antioxidants ● Plasma histamine levels correlate inversely with vitamin C levels (102) |
● Reduces I/R injury and lung damage in experimental models (65) ● Reduces pulmonary inflammation (104) ● Reduces mortality in ARDS (105) ● Prevents/ameliorates pneumonia (106, 107) |
× | × | × | × | × | |
| Renal system | ● Renal excretion | Contrast mediated nephropathy | ● Drug toxicity | ● Decreases risk for AKI (89) | × | × | ||||
| COVID-19 SIRS |
● Systemic inflammation and oxidative stress ● Vitamin C can reduce the expression of ACE2, which hinders the entry of the virus into cells, and stabilizes blood pressure (108) |
● In experimental models: protects kidneys from injuries caused by external factors, facilitates repair (108) | × | × | ||||||
| Oncology | ● Induces pluripotent stem cell differentiation ● Drug metabolism |
Chemo- and radiotherapy | ● Reduced uptake due to anorexia and cachexia ● Drug toxicity ● Reduced organ function ● Clotting disorder |
● Decreases drug toxicity (90) ● Attenuation of apoptosis and DNA damage (91) ● Decreased intestinal mucosa damage in experimental design (109) ● Increases chemosensitivity |
× | × | x | |||
| Critical illness | ● Frequent vitamin C deficiency (73–75) ● Drug metabolism |
Sepsis/septic shock, |
● Systemic inflammation ● Imbalance between vitamin C loss/requirements and vitamin C uptake |
● Reduces vasopressor requirement (86, 87) ● Reduces mortality (86, 87, 105, 110, 111) and organ failure (87) ● Shortens ICU stay (111) |
× | × | × | × | × | × |
| Burn injury | ● Induces pluripotent stem cell differentiation ● Collagen and carnitine synthesis |
Severe thermal injury with large% TBSA burned Inhalation trauma |
● I/R Injury and subsequent oxidative stress ● Hemodilution ● Large wound surfaces and increased losses ● “After-burn” and disturbed microperfusion |
● Reduction of resuscitation volume (112–114) ● Shorter time to wound healing (115) ● Reduces vasopressor requirement (113) ● Increases urine output (113, 116) ● Shorter mechanical ventilation (112) ● Improved hospital survival (117) |
× | × | × | × | × | × |
ACE II, angiotensin converting enzyme II; ARDS, acute respiratory distress syndrome; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; ICP, intracranial pressure; ICU, intensive care unit; ICB, intracranial bleeding; I/R, ischemia- and reperfusion; MI, myocardial infarction; NO, nitric oxide; SIRS, systemic inflammatory response syndrome; TBSA, total body surface area.